Baby food recalled in the US over fears it contains lead. Here's everything we know
ADVERTISEMENT
Baby food made for a major commercial retailer has been recalled in the United States over concerns it may have been tainted with elevated levels of lead.
Miami-based company Fruselva, which makes baby food sold under a Target store brand, issued the recall in March for more than 25,000 packages because they may contain traces of the heavy metal.
Products recalled include Target's Good & Gather Baby Pea, Zucchini, Kale & Thyme Vegetable Puree, sold in 4-ounce tubs, according to the US Food and Drug Administration (FDA).
Related
Butter recalled in the US after possible contamination with fecal bacteria. Here's what we know
The packages include lot number 4167, with a best-by date of December 7, and lot number 4169, with a best-by date of December 9.
Consumers should not feed babies the products.
It comes amid a series of major recalls in the country, including butter made by a Vermont-based company that
contained bacteria
commonly found in feces.
What happens if you consume lead?
The recall is listed as Class II, which means the products are unlikely to cause serious harm, but still have the potential to result in temporary or reversible problems.
There is no safe level of exposure to lead for children, according to the US Centers for Disease Control and Prevention (CDC).
Exposure to heavy metals like lead can cause developmental and cognitive problems.
Related
Shampoo recalled over possible contamination with infection-causing bacteria. Here's what we know
What are the symptoms of lead poisoning?
According to the Mayo Clinic, symptoms are initially hard to detect and usually only appear once significant or dangerous amounts have accumulated in the body.
Particularly in children under the age of 6, lead poisoning is likely to lead to developmental delays and learning difficulties, the clinic advises.
Other symptoms include irritability, weight loss, loss of appetite, abdominal pain, fatigue, and seizures.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
2 hours ago
- Euronews
L'Oréal acquires a majority stake in British skincare brand Medik8
L'Oréal has acquired a majority stake in the UK's Medik8 as it seeks to expand its position in the skincare market, the French beauty giant confirmed on Monday. As part of the deal, private equity firm Inflexion will remain a minority shareholder, and the current management committee will also stay in their roles. The cost of the stake is officially undisclosed, although the Financial Times reported last week that the potential deal was worth around €1bn. L'Oréal's share price was roughly unchanged on the news. 'We are delighted to welcome Medik8 to the L'Oréal family,' said Cyril Chapuy, President of L'Oréal LUXE. 'As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio,' he added. L'Oréal has been seeking to capitalise on the boom in science-driven skincare, partly driven by social media influencers. Brands already under its 'Dermatological Beauty Division' include La Roche-Posay, Cerave, Vichy, Skinceuticals, and Skinbetter Science. This unit brought in over €7bn in revenue in 2024, representing an almost 10% year-on-year rise, making it L'Oréal's fastest-growing division. Seeking to expand its portfolio, L'Oréal bought soap maker Aesop in 2023, and Korean beauty brand Dr.G in December. Last year, L'Oréal also acquired a 10% stake in skincare firm Galderma, as well as acquiring the beauty licence for Miu Miu. At the time of the Galderma deal, the French firm said it was 'increasingly investing in a more holistic approach, spanning the entire beauty routine' — thereby 'anticipating and intercepting the signs of skin ageing'. Medik8, founded in 2009, specialises in anti-ageing treatments and was bought by UK-based private equity firm Inflexion in 2021. Media conglomerate Warner Bros. Discovery announced on Monday that it would split into two public companies by next year, carving off its TV network operations from its streaming service. The move to spin off one company devoted to streaming and a second devoted to traditional television comes as the company struggles with a decline in overall business. The organisation said the new Streaming & Studios group would include Warner Bros. Television, Warner Bros. Motion Picture Group, DC Studios, HBO and HBO Max as well as their film and television libraries. The Global Networks company will include CNN, TNT Sports, Discovery+ and other digital products. Shares in the company jumped more than 9% ahead of the market opening. Current Warner Bros. Discovery CEO David Zaslav will continue as the head of Streaming & Studios, while the company's chief financial officer Gunnar Wiedenfels will become CEO of Global Networks. Both executives will continue in their current positions until the company separates. 'By operating as two distinct and optimised companies in the future, we are empowering these iconic brands with the sharper focus and strategic flexibility they need to compete most effectively in today's evolving media landscape,' Zaslav said in a statement. The US media giant said the split would unlock value for shareholders and create opportunities for both businesses. The split still needs final approval from the company's board but is expected to be completed by the middle of next year. Warner Bros. Discovery was created only three years ago after a merger between Warner Media and Discovery.
Fashion Network
6 hours ago
- Fashion Network
L'Oreal expands dermatological skincare portfolio with Medik8 deal
L'Oreal will acquire British skincare brand Medik8, Britain-based private equity firm Inflexion said on Monday, as the French cosmetics giant boosts its offering in the fast-growing dermatological skincare market. Neither party disclosed the size of the deal. Medik8 produces vitamin A-based anti-aging creams and serums. "The partnership with L'Oreal will allow Medik8 to deepen its presence in existing markets and expand globally. As part of the transaction, Inflexion will retain a minority shareholding in Medik8," the private equity firm said in a statement. L'Oreal's dermatological beauty division, which includes major brands like CeraVe, La Roche-Posay and SkinCeuticals, has remained its fastest-growing unit in recent years. The division generated 7 billion euros ($7.99 billion) in revenue last year, marking a growth of nearly 10% compared to the previous year. The business also delivers the highest profit margin among L'Oreal's four divisions. Consumer interest in science-backed products has driven the division's growth, though rising competition has recently slowed that momentum. L'Oreal executives said this year they are pursuing acquisitions to revive slowing growth. The company acquired Korean skincare brand Dr.G in December and also bought a minority stake in Oman-based perfume house Amouage last year. ($1 = 0.8757 euros)
Fashion Network
7 hours ago
- Fashion Network
L'Oreal expands dermatological skincare portfolio with Medik8 deal
L'Oreal will acquire British skincare brand Medik8, Britain-based private equity firm Inflexion said on Monday, as the French cosmetics giant boosts its offering in the fast-growing dermatological skincare market. Neither party disclosed the size of the deal. Medik8 produces vitamin A-based anti-aging creams and serums. "The partnership with L'Oreal will allow Medik8 to deepen its presence in existing markets and expand globally. As part of the transaction, Inflexion will retain a minority shareholding in Medik8," the private equity firm said in a statement. L'Oreal's dermatological beauty division, which includes major brands like CeraVe, La Roche-Posay and SkinCeuticals, has remained its fastest-growing unit in recent years. The division generated 7 billion euros ($7.99 billion) in revenue last year, marking a growth of nearly 10% compared to the previous year. The business also delivers the highest profit margin among L'Oreal's four divisions. Consumer interest in science-backed products has driven the division's growth, though rising competition has recently slowed that momentum. L'Oreal executives said this year they are pursuing acquisitions to revive slowing growth. The company acquired Korean skincare brand Dr.G in December and also bought a minority stake in Oman-based perfume house Amouage last year. ($1 = 0.8757 euros)
